Harold David Gunn
17Patents
8h-index
13Co-inventors
69Inventor score
Filing activity: Aug 1, 2000 → Jan 21, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7293231B1 | Data entry for personal computing devices | Physics | 147 | Expired |
| US7716579B2 | Data entry for personal computing devices | Physics | 77 | Expired |
| US7921361B2 | Data entry for personal computing devices | Physics | 73 | Active |
| US9320787B2 | Tissue targeted antigenic activation of the immune response to treat cancers | Physics | 14 | Active |
| US8034359B2 | Tissue targeted antigenic activation of the immune response to cancers | Human Necessities | 12 | Active |
| US9107864B2 | Tissue targeted antigenic activation of the immune response to treat cancers | Emerging Cross-Sectional Technologies | 11 | Active |
| US8501198B2 | Tissue targeted antigenic activation of the immune response to treat cancers | Physics | 8 | Active |
| US7681124B2 | Data entry for personal computing devices | Physics | 8 | Active |
| US8980279B2 | Personalized site-specific immunomodulation | Emerging Cross-Sectional Technologies | 6 | Active |
| US9320788B2 | Tissue targeted antigenic activation of the immune response to treat cancers | Physics | 5 | Active |
| US10130692B2 | Immunogenic anti-inflammatory compositions | Emerging Cross-Sectional Technologies | 4 | Active |
| US9775896B2 | Tissue targeted antigenic activation of the immune response to treat cancers | Emerging Cross-Sectional Technologies | 3 | Active |
| US10251946B2 | Anti-microbial immunomodulation | Emerging Cross-Sectional Technologies | 3 | Active |
| US10946083B2 | Anti-microbial immunomodulation | Emerging Cross-Sectional Technologies | 2 | Active |
| US10086066B2 | Tissue targeted antigenic activation of the immune response to treat cancers | Emerging Cross-Sectional Technologies | 1 | Active |
| US11819543B2 | Anti-microbial immunomodulation | Emerging Cross-Sectional Technologies | 0 | Active |
| US11226340B2 | Therapeutically triggering an innate immune response in a target tissue | Physics | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.